U.S. Health and Human Services Secretary Robert F. Kennedy Jr. announced a new federal initiative to build a comprehensive autism data platform using Medicare and Medicaid records. Designed to study the causes of autism spectrum disorder (ASD), the platform will integrate claims data, electronic health records, and data from wearable health devices, according to the Department of Health and Human Services (HHS).
The National Institutes of Health (NIH) and the Centers for Medicare and Medicaid Services (CMS) will collaborate on the effort, which is part of a broader $50 million research initiative to investigate potential environmental and medical causes of autism. Kennedy stated the project aims to provide "honest answers families have waited far too long to hear," despite his controversial history promoting a debunked link between vaccines and autism.
HHS said the platform will help researchers analyze autism diagnoses, treatment outcomes, healthcare access disparities, and the financial impact on families. However, experts like Dr. Helen Tager-Flusberg of Boston University argue the focus does not directly address autism’s root causes. She also noted that an existing NIH autism database recently went offline without explanation, raising concerns about transparency.
The project has sparked privacy questions, as HHS has not confirmed whether the database will be anonymous or voluntary. Autism researcher Eric Rubenstein noted that Medicaid and Medicare data offer insights into health disparities but lack environmental exposure data, which Kennedy claims he will explore.
Autism rates have surged in recent years, with the CDC reporting 1 in 31 U.S. 8-year-olds diagnosed in 2022. While Kennedy aims to identify autism’s causes by September, scientists emphasize that autism likely stems from a complex mix of genetic and environmental factors. Critics warn against oversimplifying this ongoing scientific challenge.


California, 18 States Sue to Block Trump’s $100,000 H-1B Visa Fee
Major Drugmakers Slash U.S. Prices and Sell Directly to Patients Amid Trump’s Push for Affordable Medicines
China to Add Eli Lilly’s Mounjaro to National Health Insurance in 2025
CFPB to Review Anti-Discrimination Policies and Fair Lending Rules Amid Policy Shift
U.S. Backs Bayer in Supreme Court Battle Over Roundup Cancer Lawsuits
Trump’s Approval of AI Chip Sales to China Triggers Bipartisan National Security Concerns
Trump Administration Unveils High-Priced “Trump Gold Card” Visa Program
Federal Judge Blocks Trump Administration’s Pause on New Wind-Energy Permits
EU Court Cuts Intel Antitrust Fine to €237 Million Amid Long-Running AMD Dispute
FDA Memo Raises Questions About Possible COVID-19 Vaccine Links to Rare Child Deaths
Obamacare Premiums Set to Double in 2026 as Subsidy Expiration Looms Amid U.S. Shutdown
U.S. Justice Department Orders Intensified Probe Into Antifa and Domestic Extremist Groups
Novo Nordisk Appoints Greg Miley to Lead Corporate Affairs Amid U.S. Drug Pricing Pressure
Novartis to Acquire Avidity Biosciences for $12 Billion to Strengthen Rare Muscle Disorder Portfolio
U.S. State Department Reverts to Times New Roman in Push for “Professionalism” 



